Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

A series of recent changes could have significant implications for how Americans receive and pay for their shots.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

The action will remove from use the very few flu shots that contain the contested preservative, elevating unproven fears it ...

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.